COMMUNIQUÉS West-GlobeNewswire

Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors - Corrected Version
21/05/2019
Santa Monica, CA, May 21, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet [...]
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
21/05/2019
Valby, Denmark, 21 May 2019 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck. 1. Details of [...]
MediPharm Labs Announces Addition to $1.2B MJ ETFMG Alternative Harvest ETF (USA)
21/05/2019
TORONTO, May 21, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased [...]
Emerald Health Therapeutics tiendra une conférence téléphonique sur ses résultats financiers du premier trimestre 2019 le 31 mai prochain
21/05/2019
VANCOUVER, Colombie-Britannique, 21 mai 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc (« Emerald ») (TSXV : EMH ; OTCQX : EMHTF) tiendra sa conférence téléphonique sur les résultats financiers du premier [...]
Metacrine to Present at Jefferies 2019 Global Healthcare Conference
21/05/2019
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, [...]
Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
21/05/2019
LAVAL, Québec, May 21, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of [...]
Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors
21/05/2019
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for [...]
Emerald Health Therapeutics to Hold Conference Call on First Quarter 2019 Financial Results on May 31st
21/05/2019
VANCOUVER, British Columbia, May 21, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc.(“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will host its first quarter 2019 financial results conference call on Friday, May 31 [...]
BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial
21/05/2019
NDA filing on-track for Q4 2019 RESEARCH TRIANGLE PARK, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the randomized (n=121), double-blind, placebo-controlled [...]
Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting
21/05/2019
NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies
21/05/2019
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics ® , today announces expansion of space and testing [...]
Transactions in relation to share buyback program
21/05/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 1, 2019, in accordance with article 5 of Regulation (EU) no. 596/2014 of April 16, 2014 on [...]
Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University of Basel, Co-Financed by Innosuisse
21/05/2019
Pratteln, Switzerland, May 21, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces its collaboration with the Biozentrum of the University of Basel to advance gene therapy research for the treatment of LAMA2-deficient [...]
Motif Bio to Present Iclaprim Data at ASM Microbe 2019
21/05/2019
NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that three iclaprim abstracts have [...]
Preclinical study of GKT831 shows rapid regression of cholestatic fibrosis in model of advanced liver fibrosis
21/05/2019
Publication of GKT831 data in the Journal of Hepatology Data consistent with anti-fibrotic activity recently demonstrated in PBC Phase 2 trial of GKT831 Data further support broad therapeutic potential of GKT831 in [...]
Une étude préclinique du GKT831 montre une régression rapide de la fibrose cholestatique dans un modèle de fibrose hépatique avancée
21/05/2019
Publication des donnees du GKT831 dans le Journal of Hepathology Les données répliquent l’activité anti-fibrotique récemment démontrée dans l’étude de phase 2 avec le GKT831 dans la cholangite biliaire primitive Les [...]
Anne ABRIAT-HEMMENDINGER appointed to the Board of Directors of DEINOVE
21/05/2019
Her proven experience in the beauty industry, particularly within the L'Oréal Group, will be a key asset in DEINOVE's innovation approach This appointment underlines the importance of the bioactive compounds and the [...]
Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville
21/05/2019
- Curetis and EIB agree on equity-linked participation upon maturity of new EUR 5 million tranche of debt financing - Yorkville to provide funding of EUR 1.5 million to Curetis Amsterdam, the Netherlands, and [...]
Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion
21/05/2019
Transaction is result of comprehensive capital structure and strategic review conducted independently by both Novelion’s and Aegerion’s Boards of Directors Aegerion will continue to make available to patients its two [...]

Pages